Investment in First-in-Class anti-viral drug development
Synklino is a Danish biotech company developing groundbreaking therapies for treatment of patients with chronic viral infections. The company is owned by renowned Nordic funds and institutional investors PKA Pension Fund, Eir Ventures, and Denmark’s Export and Investment Fund as well as approximately 70 private shareholders.
1 January – 31 December
Synklino has scheduled the following dates for the upcoming release of Annual report and Annual General Meeting. You will also find links to previous Annual reports.